Celgene/Bristol's Revlimid Patent Risk Incrementally Lower After PTAB Denies Alvogen IPR

The final request for an inter partes review (IPR) of a Celgene Corp.Revlimid (lenalidomide) patent by the US Patent and Trademark Office (USPTO) Patent Trial and Appeal Board (PTAB) was denied March 14, somewhat reducing the intellectual property risk associated with Bristol-Myers Squibb Co.'s pending $74bn acquisition of the company.

Bristol-Myers has tried to keep investors focused on Celgene's research and development pipeline, which is designed to eventually replace the loss of Revlimid's blockbuster revenue stream, as an April 12 shareholder vote on the Celgene deal approaches